Characteristics of our hypoxemic COVID-19 pneumonia patients receiving corticosteroids and mortality-associated factors

Basit Öğe Kaydı
dc.authoridOzdemir, Ozer/0000-0002-8884-0682
dc.authoridSatici, Celal/0000-0002-5457-9551
dc.authoridSen, Nazan/0000-0002-4171-7484
dc.authoridAydemir, Yusuf/0000-0003-2479-2949
dc.authoridSengul, Aysun/0000-0002-8084-1322
dc.authoridSoyler, Yasemin/0000-0002-0507-0767
dc.contributor.authorSengul, Aysun
dc.contributor.authorMutlu, Pinar
dc.contributor.authorOzdemir, Ozer
dc.contributor.authorSatici, Celal
dc.contributor.authorTuran, Muzaffer Onur
dc.contributor.authorArslan, Sertac
dc.contributor.authorOgang, Nalan
dc.date.accessioned2025-03-23T19:34:42Z
dc.date.available2025-03-23T19:34:42Z
dc.date.issued2022
dc.departmentSinop Üniversitesi
dc.description.abstractBackground COVID-19 is a disease associated with diffuse lung injury that has no proven effective treatment yet. It is thought that glucocorticoids may reduce inflammation-mediated lung injury, disease progression, and mortality. We aimed to evaluate our patient's characteristics and treatment outcomes who received corticosteroids for COVID-19 pneumonia. Methods We conducted a multicenter retrospective study and reviewed 517 patients admitted due to COVID-19 pneumonia who were hypoxemic and administered steroids regarding demographic, laboratory, and radiological characteristics, treatment response, and mortality-associated factors. Results Of our 517 patients with COVID-19 pneumonia who were hypoxemic and received corticosteroids, the mortality rate was 24.4% (n = 126). The evaluation of mortality-associated factors revealed that age, comorbidities, a CURB-65 score of >= 2, higher SOFA scores, presence of MAS, high doses of steroids, type of steroids, COVID-19 treatment, stay in the intensive care unit, high levels of d-dimer, CRP, ferritin, and troponin, and renal dysfunction were associated with mortality. Conclusion Due to high starting and average steroid doses are more associated with mortality, high-dose steroid administration should be avoided. We believe that knowing the factors associated with mortality in these cases is essential for close follow-up. The use of CURB-65 and SOFA scores can predict prognosis in COVID-19 pneumonia.
dc.identifier.doi10.1080/17476348.2022.2102480
dc.identifier.endpage958
dc.identifier.issn1747-6348
dc.identifier.issn1747-6356
dc.identifier.issue8
dc.identifier.pmid35839345
dc.identifier.scopusqualityQ1
dc.identifier.startpage953
dc.identifier.urihttps://doi.org/10.1080/17476348.2022.2102480
dc.identifier.urihttps://hdl.handle.net/11486/5711
dc.identifier.volume16
dc.identifier.wosWOS:000831157700001
dc.identifier.wosqualityQ2
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakPubMed
dc.language.isoen
dc.publisherTaylor & Francis Ltd
dc.relation.ispartofExpert Review of Respiratory Medicine
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı
dc.rightsinfo:eu-repo/semantics/closedAccess
dc.snmzKA_WOS_20250323
dc.subjectCOVID-19
dc.subjectcorticosteroid
dc.subjecthypoxemia
dc.subjectmortality
dc.subjectprognosis
dc.titleCharacteristics of our hypoxemic COVID-19 pneumonia patients receiving corticosteroids and mortality-associated factors
dc.typeArticle

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu